AnaptysBio (NASDAQ: ANAB) CEO gets PSU grant and sells shares for tax

Rhea-AI Filing Summary

ANAPTYSBIO, INC President and CEO Daniel Faga received 34,300 performance-based restricted stock units (PSUs) after the compensation committee certified that specific performance goals were achieved on March 25, 2026. Each PSU represents a right to receive one share of common stock.

On March 27, 2026, Faga sold an aggregate of 17,679 shares of common stock in multiple open-market transactions at weighted-average prices ranging from the mid‑$50s to mid‑$60s per share. According to the disclosure, these sales were solely to cover tax withholding obligations from the PSU vesting and were not discretionary trades.

After these grant and tax-related sales, Faga holds 495,965 shares of AnaptysBio common stock directly, indicating that the transactions reflect routine compensation vesting and associated tax settlement rather than a change in his core equity position.

Insider Trade Summary

Net Seller: 17,679 shares ($1,089,199)

Net Sell 11 txns

Insider Faga Daniel

Role President, CEO

Sold 17,679 shs ($1.09M)

Type	Security	Shares	Price	Value
Sale	Common Stock	510	$56.613	$29K
Sale	Common Stock	2,570	$57.9063	$149K
Sale	Common Stock	3,662	$58.6158	$215K
Sale	Common Stock	490	$59.6237	$29K
Sale	Common Stock	550	$60.6264	$33K
Sale	Common Stock	1,012	$62.1525	$63K
Sale	Common Stock	2,592	$63.3503	$164K
Sale	Common Stock	3,155	$64.1909	$203K
Sale	Common Stock	3,038	$65.1982	$198K
Sale	Common Stock	100	$65.99	$7K
Grant/Award	Common Stock	34,300	$0.00	--

Holdings After Transaction: Common Stock — 513,134 shares (Direct)

Footnotes (1)

1. Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 25, 2026. Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.285 to $57.215 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.29 to $58.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.29 to $59.275 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.29 to $60.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.405 to $61.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.71 to $63.685 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.71 to $64.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.785 to $65.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faga Daniel

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/25/2026		A		34,300(1)	A	(2)	513,644	D
Common Stock	03/27/2026		S(3)		510	D	$56.613(4)	513,134	D
Common Stock	03/27/2026		S(3)		2,570	D	$57.9063(5)	510,564	D
Common Stock	03/27/2026		S(3)		3,662	D	$58.6158(6)	506,902	D
Common Stock	03/27/2026		S(3)		490	D	$59.6237(7)	506,412	D
Common Stock	03/27/2026		S(3)		550	D	$60.6264(8)	505,862	D
Common Stock	03/27/2026		S(3)		1,012	D	$62.1525(9)	504,850	D
Common Stock	03/27/2026		S(3)		2,592	D	$63.3503(10)	502,258	D
Common Stock	03/27/2026		S(3)		3,155	D	$64.1909(11)	499,103	D
Common Stock	03/27/2026		S(3)		3,038	D	$65.1982(12)	496,065	D
Common Stock	03/27/2026		S(3)		100	D	$65.99	495,965	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 25, 2026.

2. Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.

3. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.285 to $57.215 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.29 to $58.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.29 to $59.275 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.29 to $60.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.405 to $61.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.71 to $63.685 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

11. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.71 to $64.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

12. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.785 to $65.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Eric Loumeau, Attorney-in-Fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did AnaptysBio (ANAB) CEO Daniel Faga receive in this Form 4?

Daniel Faga received 34,300 performance-based restricted stock units (PSUs) after performance goals were certified on March 25, 2026. Each PSU gives him the right to receive one share of AnaptysBio common stock upon vesting and settlement.

How many AnaptysBio (ANAB) shares did CEO Daniel Faga sell and at what prices?

Faga sold 17,679 shares of common stock on March 27, 2026 in multiple open-market transactions. The weighted-average sale prices ranged broadly from the mid‑$50s to the mid‑$60s per share, based on grouped price ranges disclosed.

Why were Daniel Faga’s AnaptysBio (ANAB) share sales executed?

The sales were made solely to cover tax withholding obligations arising from the vesting and settlement of PSUs. The company states the transactions were structured as a “sell to cover” and do not represent discretionary trading by Faga.

How many AnaptysBio (ANAB) shares does CEO Daniel Faga own after these transactions?

Following the PSU grant and related tax-withholding sales, Faga holds 495,965 shares of AnaptysBio common stock directly. This remaining stake shows he retains a substantial equity position after satisfying the tax obligations tied to his performance-based awards.

What are performance-based restricted stock units (PSUs) in the AnaptysBio (ANAB) filing?

In this case, PSUs are performance-based share awards that vest only when specified performance criteria are achieved and certified. Each earned PSU entitles Faga to receive one share of AnaptysBio common stock upon settlement, aligning compensation with performance results.

Do the AnaptysBio (ANAB) CEO’s sales signal a major reduction in his stake?

The reported activity shows tax-related sales of 17,679 shares linked to PSU vesting, while Faga continues to hold 495,965 shares. The pattern reflects routine compensation and tax settlement rather than a large discretionary reduction in his ownership.